Nektar Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	62.6	98.43	90.12	92.06	101.91	152.92
Revenue Growth (YoY)	-32.79%	9.21%	-2.10%	-9.67%	-33.36%	33.41%
Cost of Revenue	7.98	30.69	33.77	21.64	24.9	19.48
Gross Profit	54.62	67.74	56.35	70.42	77.01	133.44
Selling, General & Admin	74.62	76.75	77.42	92.33	122.84	104.68
Research & Development	116.36	120.91	114.16	218.32	400.27	408.68
Operating Expenses	190.99	197.66	191.58	310.66	523.11	513.36
Operating Income	-136.36	-129.92	-135.23	-240.24	-446.1	-379.92
Interest Expense	-26.57	-28.11	-25.33	-28.91	-47.31	-37.12
Interest & Investment Income	10.6	14.5	19.01	6.78	2.73	18.28
Other Non Operating Income (Expenses)	0.27	-0.39	-1.15	33.31	-8.19	-
EBT Excluding Unusual Items	-159.44	-143.92	-142.7	-229.05	-498.87	-398.76
Merger & Restructuring Charges	-2.12	-15.67	-51.96	-135.93	-	-
Impairment of Goodwill	-	-	-76.5	-	-	-
Gain (Loss) on Sale of Assets	40.39	40.39	-5.1	-	-	-
Other Unusual Items	-	-	-	-	-24.41	-45.19
Pretax Income	-121.16	-119.2	-276.26	-364.98	-523.28	-443.95
Income Tax Expense	-0.43	-0.24	-0.2	3.22	0.56	0.49
Net Income	-120.74	-118.96	-276.06	-368.2	-523.84	-444.44
Net Income to Common	-120.74	-118.96	-276.06	-368.2	-523.84	-444.44
Shares Outstanding (Basic)	15	14	13	12	12	12
Shares Outstanding (Diluted)	15	14	13	12	12	12
Shares Change (YoY)	14.07%	8.24%	1.53%	2.10%	2.64%	2.05%
EPS (Basic)	-7.90	-8.68	-21.79	-29.51	-42.87	-37.33
EPS (Diluted)	-7.90	-8.68	-21.79	-29.55	-42.90	-37.33
Free Cash Flow	-190.35	-177.18	-193.47	-309.68	-427.65	-320.55
Free Cash Flow Per Share	-12.46	-12.92	-15.27	-24.82	-35.00	-26.92
Gross Margin	87.26%	68.82%	62.53%	76.50%	75.57%	87.26%
Operating Margin	-217.83%	-131.99%	-150.05%	-260.97%	-437.76%	-248.45%
Profit Margin	-192.87%	-120.86%	-306.31%	-399.98%	-514.03%	-290.64%
Free Cash Flow Margin	-304.07%	-180.01%	-214.68%	-336.41%	-419.65%	-209.62%
EBITDA	-135.2	-125.53	-127.41	-227.21	-431.96	-365.74
EBITDA Margin	-215.97%	-127.53%	-141.38%	-246.81%	-	-239.18%
D&A For EBITDA	1.17	4.39	7.82	13.03	14.15	14.18
EBIT	-136.36	-129.92	-135.23	-240.24	-446.1	-379.92
EBIT Margin	-217.83%	-131.99%	-150.05%	-260.97%	-	-248.45%
Revenue as Reported	62.6	98.43	90.12	92.06	101.91	152.92

Updated Nov 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q